Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. (CLLS) news covers the activities of a clinical-stage biotechnology company focused on gene-edited cell and gene therapies. The company regularly issues updates on its allogeneic CAR-T pipeline, gene-editing technology advances, strategic collaborations, and financial position, providing a detailed view of how its programs evolve over time.
Investors and observers following Cellectis news can read about clinical data from key trials such as BALLI-01 for lasme-cel (UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia and NATHALI-01 for eti-cel (UCART20x22) in relapsed/refractory non-Hodgkin lymphoma. Press releases describe response rates, safety findings, and trial design features, as well as plans for pivotal Phase 2 development and data presentations at major scientific meetings.
Cellectis also publishes research and technology updates, including work on circular single-stranded DNA (CssDNA) as a non-viral donor template for gene insertion in hematopoietic stem and progenitor cells and studies of TALE base editors in primary T cells. These announcements highlight how the company applies its gene-editing platform beyond CAR-T therapies.
Additional news items address collaborations with partners such as AstraZeneca, Servier, Allogene, and Iovance, along with arbitration outcomes, financial results, cash runway disclosures, and monthly information on share capital and voting rights. By reviewing this news feed, readers can track both scientific progress and corporate developments that shape the outlook for Cellectis and its CLLS listing.
Cellectis announced promising preclinical data for its allogeneic dual CAR T-cell candidate, UCART20x22, targeting relapsed or refractory Non-Hodgkin Lymphoma (r/r NHL). The data demonstrate significant in vitro and in vivo anti-tumor activity, potentially overcoming common resistance mechanisms. UCART20x22 aims to simplify treatment by being fully developed and manufactured in-house, with an Investigational New Drug application expected this year. This marks a pivotal step in Cellectis’ strategy as it transitions to a comprehensive cell and gene therapy platform.
Cellectis, a clinical-stage biotechnology company, reported its share structure as of March 31, 2022. The company has a total of 45,490,810 shares in capital and 51,083,431 voting rights. Cellectis utilizes its gene-editing platform to develop therapies for various cancers and genetic disorders. Its UCART product candidates target diseases like acute myeloid leukemia and multiple myeloma. The company's commitment is to provide innovative therapies using its proprietary technologies, including TALEN® and PulseAgile.
Cellectis, a clinical-stage biotechnology company focused on gene editing, announced its participation in two important healthcare conferences: the Oppenheimer & Co. Annual Healthcare Conference on March 16, 2022, at 4:00 PM EST, and the Barclays Global Healthcare Conference on March 17, 2022, at 9:30 AM EST. Both events will feature live webcasts available on their investor website. Cellectis aims to advance its innovative CAR-T therapies, targeting diseases like leukemia and multiple myeloma, utilizing its proprietary gene-editing technology TALEN®.
Cellectis, a clinical-stage biotechnology company, specializes in gene-editing for cancer therapies. As of February 28, 2022, the company has a total of 45,484,310 shares in capital and 51,076,931 voting rights. Utilizing its TALEN® technology and PulseAgile system, Cellectis aims to develop allogeneic CAR-T immunotherapies for various cancers, including AML and B-ALL. The company is committed to addressing unmet medical needs in oncology and blood disorders.
Cellectis (Nasdaq: CLLS) reported its fourth quarter and full-year 2021 results, highlighting a consolidated cash position of $191 million as of December 31, 2021, down from $274 million in 2020. The company experienced a consolidated revenue decrease to $67 million from $82 million in 2020. R&D expenses rose significantly to $129 million from $87 million. Cellectis presented encouraging preliminary results for its BALLI-01 study of UCART22 at ASH 2021, with plans for an IND submission for UCART20x22 in 2022. A conference call is scheduled for March 4, 2022, to discuss results.
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biotechnology firm specializing in gene editing, will announce its financial results for the fourth quarter and the year-end 2021 on March 3, 2022, after market closure. This will be followed by a conference call on March 4, 2022, at 8:00 AM EDT, detailing its quarterly and annual results and business updates. Cellectis focuses on innovative cell and gene therapies for cancer and blood disorders, utilizing its TALEN® technology and PulseAgile electroporation system.
Cellectis, a clinical-stage biotechnology company focused on gene editing, announced an underwritten offering to an institutional investor involving Calyxt, its majority-owned subsidiary. The offering includes 3,880,000 shares of Calyxt common stock, pre-funded warrants for 3,880,000 shares, and common warrants for 7,760,000 shares, all priced at $1.41 each. As of December 31, 2021, Calyxt reported cash and cash equivalents of $13.7 million and total current liabilities of $4.1 million. The preliminary financial data is subject to audits and potential adjustments.
Cellectis, a clinical-stage biotechnology company, focuses on gene editing and cell therapies for cancer treatment. As of January 31, 2022, the total number of shares outstanding is 45,484,310, with 51,085,785 voting rights. The company aims to provide lifesaving UCART products targeting multiple cancers and has developed a new platform, .HEAL, for treating blood disorders. Cellectis strives to leverage its TALEN® technology and PulseAgile system for innovative therapies. It is listed on both Nasdaq (CLLS) and Euronext Growth (ALCLS).
Cellectis has appointed Bing C. Wang, PhD, MBA, as the new Chief Financial Officer. Wang brings extensive experience in biotechnology finance, previously serving as CEO of Refuge Biotechnologies and in investment banking with Barclays and Citigroup. He will manage Cellectis’ global finance team, aiming to enhance the company’s financial strategy during its clinical trial developments. Wang's background includes strategic capital raising and corporate finance, making him a valuable addition to Cellectis as it focuses on developing off-the-shelf cancer therapies.
Cellectis announced its share and voting rights status as of December 31, 2021. The total number of shares in capital stood at 45,484,810, while the total number of voting rights reached 51,085,782. The company specializes in gene editing and is known for its innovative CAR-T immunotherapies aimed at treating various cancers, including acute myeloid leukemia and multiple myeloma. Cellectis operates from its headquarters in Paris and has a presence in New York and North Carolina. Its commitment to developing life-saving therapies positions it as a leader in the biotech sector.
FAQ
What is the current stock price of Cellectis (CLLS)?
What is the market cap of Cellectis (CLLS)?
